AstraZeneca and Daiichi Sankyo's Enhertu, given in combination with Roche's Perjeta, has become the first new frontline ...

Roche is paying $75 million for a trispecific antibody developed by a subsidiary of China's Simcere Pharma as a treatment for ...

That’s roughly how long I have to review a patient’s history, examine her, explain my diagnosis, write a prescription, and – particularly if I’m prescribing a specialty medication – walk her through ...

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...

GSK is planning to start a phase 3 trial of the new vaccine later this month, saying it will be the first late-stage trial of ...

Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...

Nine mid-sized pharma companies have signed up for the Trump administration's Most Favoured Nation (MFN) pricing deals, ...

US President Donald Trump has nominated White House health policy aide Heidi Overton to take up the mantle of commissioner ...

Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad, the main asset in the deal. The oral, once-daily URAT1 ...

The much-anticipated pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs has arrived, with a deal that spans the current injectable products as well as ...